Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: Results of the COL-ECMO2022 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F25%3A00082400" target="_blank" >RIV/00159816:_____/25:00082400 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00142209 RIV/00216208:11110/25:10501615 RIV/61989592:15110/25:73631631 RIV/00064165:_____/25:10501615
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0924857925001372" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0924857925001372</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijantimicag.2025.107582" target="_blank" >10.1016/j.ijantimicag.2025.107582</a>
Alternative languages
Result language
angličtina
Original language name
Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: Results of the COL-ECMO2022 trial
Original language description
Introduction: Colistin is recognized as the last-resort antibiotic for treating infections caused by multidrug-resistant Gram-negative bacteria, especially in critically ill patients. However, its interference with the extracorporeal membrane oxygenation (ECMO) circuit may affect the achievement of therapeutic targets. The COL-ECMO2022 study aimed to verify the interference of colistin and its prodrug colistimethanesulphonate (CMS) with ECMO. Methods: A prospective pharmacokinetic phase IV study included critically ill adults in whom the parenteral colistin was part of standard medical care. A maximum of three dosing intervals were monitored for each patient. CMS and colistin concentrations were measured by HPLC-MS. ECMO and non-ECMO patients were compared by average steady-state colistin concentration (CAVG,SS ), population pharmacokinetic model (ECMO as a covariate), and linear mixed-effect model (LMEM). Results: Eighteen patients and 40 monitored dosing intervals were analyzed. Median CAVG,SS was nonsignificantly lower in 7 patients on ECMO (4.3 [3.5-6.3] mg/L) than in 11 non-ECMO patients (5.2 [4.2- 11.5] mg/L) (by 18%; P = 0.551). ECMO was not a significant covariate for any pharmacokinetic parameter in the population PK model. Although LMEM proved significant adsorption of CMS on the ECMO circuit, colistin concentrations were not significantly influenced. Conclusion: No significant differences in colistin plasma concentrations were detected; therefore, CMS dosage adjustment is unnecessary in patients on ECMO. (c) 2025 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30200 - Clinical medicine
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Antimicrobial Agents
ISSN
0924-8579
e-ISSN
1872-7913
Volume of the periodical
66
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
107582
UT code for WoS article
001558990000001
EID of the result in the Scopus database
—